Internal Program 2

About AbCellera

AbCellera is a pioneer in AI-powered antibody discovery, operating a unique platform that integrates microfluidics, high-throughput screening, and machine learning to rapidly identify therapeutic antibodies from natural immune responses. The company's business model is primarily partnership-driven, collaborating with major pharmaceutical companies to advance drug candidates while also building its own pipeline. Key achievements include its critical role in the discovery of bamlanivimab for COVID-19 and its successful IPO in 2020. Its strategic direction focuses on expanding its internal pipeline, scaling its platform capabilities, and deepening its partnerships across multiple therapeutic areas.

Therapeutic Areas